What is the clinical evidence from this study?

Study design: Review. Population: Immune checkpoint inhibitor-associated myocarditis. Intervention: Immune checkpoint inhibitors.

What question did this study set out to answer?

To summarize the diagnostic and therapeutic strategies for immune checkpoint inhibitor-associated myocarditis.

July 7, 2021JAMA Cardiology

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis

View Full Paper

Ask AI

Bookmark

Key result

Combination therapy with a CTLA-4 inhibitor and a PD-1 or PD-L1 inhibitor increases the risk of developing immune checkpoint inhibitor-associated myocarditis.

Why the study?

Immune checkpoint inhibitor-associated myocarditis is a significant and potentially fatal adverse effect, presenting new diagnostic and therapeutic challenges for practicing clinicians.

Key Points

To summarize the diagnostic and therapeutic strategies for immune checkpoint inhibitor-associated myocarditis.
Review of current literature on ICI-associated myocarditis
Combination of clinical suspicion, cardiac biomarkers, imaging, and biopsy for diagnosis
Focus on clinical presentation and variability in cardiac pathology.
Patients with ICI-associated myocarditis show variable clinical presentations and pathological findings.
Endomyocardial biopsy remains the standard diagnostic test but is often supplemented with other methods.
Combination therapies with specific ICIs increase the risk of myocarditis.

Structured PICO

Population

Patients with suspected immune checkpoint inhibitor-associated myocarditis

Exposure

Standardized diagnostic and therapeutic approach including clinical history, physical examination, cardiac biomarkers (specifically troponin), cardiac imaging, and endomyocardial biopsy

This review outlines a standardized, multimodality diagnostic and therapeutic approach for managing the potentially fatal complication of immune checkpoint inhibitor-associated myocarditis.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Demands heightened vigilance for ICI myocarditis in cancer care; leaves open standardized diagnostic and therapeutic protocols.

Cite This Study

Lehmann et al. (2021) conducted a review in Immune checkpoint inhibitor-associated myocarditis. Immune checkpoint inhibitors was evaluated. Combination therapy with a CTLA-4 inhibitor and a PD-1 or PD-L1 inhibitor increases the risk of developing immune checkpoint inhibitor-associated myocarditis.

synapsesocial.com/papers/6a3302ce7282da616280753d https://doi.org/10.1001/jamacardio.2021.2241

Topics

Myocarditis Cardiac imaging

View Full Paper

Ask AI

Bookmark

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider